Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS-03 combined with FOLFOX or FOLFIRI plus bevacizumab in RAS-mutant metastatic colorectal cancer
CTR20251111Phase 2Active
- Sponsor
- CSPC Xingsheng Xinhui Pharmaceutical
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XS-03 in colorectal cancer (CRC), sponsored by CSPC Xingsheng Xinhui Pharmaceutical. Started May 2025; status: active.
02
Drugs
XS-03
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20251111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251111.